AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19274516
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of three disease-modifying anti-rheumatic drugs (DMARDs)
Trial: 19274516
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of three DMARDs
Trial: 16679098
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors (160 subjects receiving treatment)
Trial: 16679098
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors (short duration <3 years)
Trial: 16679098
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors (long duration 3 to 9 years)
Trial: 16679098
Drug: Non-receiving ACE
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-receiving ACE inhibitors (rest of study population)
Trial: 15599144
Drug: Oxygen therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen therapy, CPAP, Bilevel-PAP
Trial: 16161718
Drug: Double versus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double versus triple antiretroviral therapy
Trial: 11079534
Drug: Citicoline (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citicoline (500 mg/day) for 6 weeks
Trial: 11079534
Drug: Citicoline (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citicoline (500 mg/day)
Trial: 27686226
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg mirabegron once daily
Trial: 27686226
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg imidafenacin twice daily
Trial: 22853865
Drug: Fesoterodine SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesoterodine SR 4 mg
Trial: 22853865
Drug: Fesoterodine SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesoterodine SR 8 mg
Trial: 20164809
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acids (N3) - 2000 mg eicosapentaenoic acid and 400 mg docosahexaenoic acid
Trial: 20164809
Drug: Vitamin-mineral complex
RxNorm normalized name: vitamin B complex
DrugBank: Dexpanthenol (DB09357)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin-mineral complex (VM) - vitamins C (2000 mg), E (800 IU), A (3000 IU), selenium (200 microg)
Trial: 20164809
Drug: Vitamin-mineral complex
RxNorm normalized name: vitamin B complex
DrugBank: Dexpanthenol (DB09357)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin-mineral complex and n-3 fatty acid combination (VN3)
Trial: 17914135
Drug: Low vitamin
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low vitamin D stores (18 ng/ml)
Trial: 17914135
Drug: Adequate vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adequate vitamin D stores (>34 ng/ml)
Trial: 7779152
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg aciclovir tablet (test formulation)
Trial: 7779152
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg aciclovir tablet (reference formulation)
Trial: 7779152
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg aciclovir tablet (test formulation)
Trial: 7779152
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg aciclovir tablet (reference formulation)
Trial: 11198725
Drug: Flurbiprofen 8.75
RxNorm normalized name: flurbiprofen 8.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 8.75 mg
Trial: 12658471
Drug: Eptifibatide plus
RxNorm normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eptifibatide plus heparin
Trial: 7535676
Drug: Colchicine (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (0.6 mg twice daily)
Trial: 6313561
Drug: Hemibody radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hemibody radiation (HBI) as a consolidating-maintenance agent
Trial: 31343010
Drug: α-lipoic acid
RxNorm normalized name: α-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α-lipoic acid (α-LA) supplementation (1200 mg/day, 600 mg per capsule, 2 capsules daily)
Trial: 31343010
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules (2 capsules daily)
Trial: 28891772
Drug: Cognitive-Behavioral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Therapy plus Hypnosis
Trial: 26934084
Drug: Watermelon extract
RxNorm normalized name: watermelon extract 50 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Watermelon extract (6 g daily for 42 days)
Trial: 26934084
Drug: Watermelon extract
RxNorm normalized name: watermelon extract 50 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Watermelon extract (6 g daily for 42 days) in carriers of the T allele (MTHFR C677T)
Trial: 23082849
Drug: Total Disc
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Disc Replacement (TDR) with ProDisc-L
Trial: 19497646
Drug: MCT/LCT lipid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCT/LCT lipid emulsion (M/L)
Trial: 14630619
Drug: Sitaxsentan 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitaxsentan 300 mg
Trial: 11781553
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg atropine intravenously (i.v.)
Trial: 7522392
Drug: Thick, energy-dense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thick, energy-dense porridge (4.09 kJ/g)
Trial: 7522392
Drug: Traditional liquid,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional liquid, low-density porridge (2.15 kJ/g)
Trial: 12915681
Drug: Spironolactone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (25 mg/d)
Trial: 16179584
Drug: Eplerenone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone (200 mg.kg(‐1).d(‐1))
Trial: 16179584
Drug: Aldosterone (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldosterone (250 nmol/L)
Trial: 16179584
Drug: Eplerenone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone (2 micromol/L)
Trial: 11874386
Drug: Alosetron (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alosetron (2 mg, single oral and intravenous doses)
Trial: 2202512
Drug: Ceftizoxime 2
RxNorm normalized name: ceftizoxime 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftizoxime 2 gm intravenously every 12 hours with doxycycline 100 mg intravenously twice daily (Rx 1)
Trial: 2202512
Drug: Cefoxitin 2
RxNorm normalized name: cefoxitin 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin 2 gm intravenously every six hours with doxycycline 100 mg intravenously twice daily (Rx 2)
Trial: 2202512
Drug: Ceftizoxime 2
RxNorm normalized name: ceftizoxime 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftizoxime 2 gm intravenously every eight hours with doxycycline 100 mg intravenously twice daily (Rx 3)
Trial: 2202512
Drug: Clindamycin 900
RxNorm normalized name: clindamycin 900 MG in 6 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin 900 mg intravenously every eight hours with a 2‐mg/kg loading dose of gentamicin followed by 1.5 mg/kg intravenously every eight hours (Rx 4)
Trial: 31532808
Drug: Shorter distance
RxNorm normalized name: Cistanche tinctoria stem extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shorter distance to the treatment site
Trial: 26486166
Drug: Ezetimibe/Simvastatin 10/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe/Simvastatin 10/20 mg (ES10/20)
Trial: 26486166
Drug: Statin dose-doubling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin dose-doubling (to S40 or A20)
Trial: 23374898
Drug: Rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10 mg (R10)
Trial: 21554401
Drug: DFX-40 (deferasirox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFX-40 (deferasirox 40 mg/kg/d for 6 months)
Trial: 21554401
Drug: DFX-20 (deferasirox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFX-20 (deferasirox 20 mg/kg/d for 6 months)
Trial: 12630983
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide (TA) 220 micro g
Trial: 12630983
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate (MF) 200 micro g
Trial: 31332020
Drug: selinexor plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: selinexor plus low-dose dexamethasone
Trial: 16245263
Drug: Metoclopramide (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (30 mg)
Trial: 9286225
Drug: Guar gum
RxNorm normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guar gum (5 g) with water (300 ml)
Trial: 9286225
Drug: Guar gum
RxNorm normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guar gum (5 g) with glucose drink (300 ml/330 kcal)
Trial: 9286225
Drug: Guar gum
RxNorm normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guar gum (5 g) with solid meal (530 kcal)
Trial: 8364350
Drug: Fluoxetine 40
RxNorm normalized name: fluoxetine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 40 mg or 60 mg daily
Trial: 8364350
Drug: Fluoxetine (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (any dose)
Trial: 3108527
Drug: CS-514 5
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-514 5 mg
Trial: 3108527
Drug: CS-514 20
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-514 20 mg
Trial: 3108527
Drug: CS-514 40
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-514 40 mg
Trial: 3108527
Drug: CS-514 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-514 (all doses)
Trial: 26596801
Drug: Intraperitoneal implantation
RxNorm normalized name: Intraperitoneal Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal implantation of sustained-release 5-fluorouracil 600 mg as local chemotherapy
Trial: 23332619
Drug: Doxycycline 40
RxNorm normalized name: Doxycycline 40 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 40 mg capsules orally once daily for 16 weeks
Trial: 23332619
Drug: Placebo 40
RxNorm normalized name: placebo 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 40 mg capsules orally once daily for 16 weeks
Trial: 2656042
Drug: MAb 96.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAb 96.5 as first infusion
Trial: 2656042
Drug: MAb 96.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAb 96.5 as second infusion
Trial: 2656042
Drug: ZME-018 as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZME-018 as first infusion
Trial: 2656042
Drug: ZME-018 as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZME-018 as second infusion
Trial: 31067356
Drug: Irinotecan with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan with vincristine (VI) followed by multi-agent chemotherapy for 44 weeks
Trial: 31067356
Drug: Multi-agent chemotherapy
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-agent chemotherapy including tirapazamine (TPZ) for 31 weeks
Trial: 31067356
Drug: Multi-agent chemotherapy
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-agent chemotherapy without VI and TPZ for 31 weeks
Trial: 29746672
Drug: Sarilumab 200
RxNorm normalized name: SARILUMAB 200MG/1.14ML INJ SYR 1.14ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarilumab 200 mg q2w plus MTX
Trial: 29746672
Drug: Sarilumab 150
RxNorm normalized name: SARILUMAB 150MG/1.14ML INJ SYR 1.14ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarilumab 150 mg q2w plus MTX
Trial: 27165711
Drug: Edoxaban 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban 90 mg/day for 10 days followed by 60 mg/day
Trial: 27165711
Drug: Parenteral anticoagulation
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral anticoagulation bridging to warfarin for 3 months
Trial: 26280592
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment condition (AT; n = 31)
Trial: 26280592
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment condition (CT; n = 31)
Trial: 19808428
Drug: Higher HR
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher HR on in-treatment ECGs
Trial: 19808428
Drug: Higher in-treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher in-treatment HR
Trial: 16650165
Drug: Desloratadine treatment
RxNorm normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desloratadine treatment for 4 weeks
Trial: 2080486
Drug: 1 tablet
RxNorm normalized name: Ovral-21 Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of althiazide (15 mg) and spironolactone (25 mg)
Trial: 2080486
Drug: 2 tablets
RxNorm normalized name: Voydeya 150 MG Dose Card Pack, 4 Blister Cards, 42 Tablets Each
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets of althiazide (15 mg) and spironolactone (25 mg)
Trial: 15725969
Drug: Methylphenidate 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate 0.3 mg/kg
Trial: 337493
Drug: Methylphenidate 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate 1.0 mg/kg
Trial: 29565195
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 (PGE2) agents - propess
Trial: 29565195
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 (PGE2) agents - prostin
Trial: 29565195
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of propess and prostin
Trial: 20357375
Drug: Sitagliptin (4-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin (4-week treatment)
Trial: 16155380
Drug: Milrinone in
RxNorm normalized name: milrinone Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milrinone in combination with inhaled nitric oxide (iNO)
Trial: 12862328
Drug: Malarone (atovaquone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Malarone (atovaquone 250 mg/proguanil 100 mg)
Trial: 12862328
Drug: Primaquine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primaquine (30 mg of base)
Trial: 10979164
Drug: Osteopathic manipulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic manipulative treatment on postoperative days 2 through 5
Trial: 3555355
Drug: Dakin's solution
RxNorm normalized name: Sodium Hypochlorite 0.5% Topical application Solution [DAKIN'S SOLUTION FULL STRENGTH]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dakin's solution (chloramine‐T)‐soaked wet‐to‐dry dressings
Trial: 28811354
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg QD
Trial: 28811354
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg QD
Trial: 22076246
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg dexamphetamine
Trial: 22076246
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg dexamphetamine + 0.8 g/kg alcohol
Trial: 18767576
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group with oral administration of Qianliekang tablets
Trial: 9891521
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with carboplatin and ifosfamide (11 patients)
Trial: 9891521
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with carboplatin and paclitaxel (3 patients)
Trial: 9891521
Drug: No neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No neoadjuvant chemotherapy (6 patients with no change)
Trial: 2691483
Drug: Single pre-operative
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single pre-operative dose of 2.2 g amoxycillin/clavulanate
Trial: 2691483
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 1.5 g cefuroxime plus 0.5 g metronidazole
Trial: 371733
Drug: Conventional compound
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional compound (methylglucamine‐ioxitalamate)
Trial: 28606661
Drug: VR training
RxNorm normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VR training using Xbox Kinect plus conventional physical therapy (30 minutes each)
Trial: 28606661
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy only (30 minutes)
Trial: 28606661
Drug: VR training
RxNorm normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VR training using Xbox Kinect plus conventional physical therapy
Trial: 21418260
Drug: Pancrelipase delayed-release
RxNorm normalized name: Pancrelipase Delayed-Release Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancrelipase delayed-release capsules (Creon) at a mean dose of 186960±74640 lipase units/day
Trial: 21418260
Drug: Pancrelipase delayed-release
RxNorm normalized name: Pancrelipase Delayed-Release Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancrelipase delayed-release capsules (Creon)
Trial: 15084794
Drug: Donepezil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (10 mg daily) plus cognitive training (images of everyday life and reminiscent music, 3 sessions per week for 12 months)
Trial: 11284571
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment using a Herbert bone screw
Trial: 11284571
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment using a cast
Trial: 2519941
Drug: 1 gram
RxNorm normalized name: guar gum 1 gram ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 gram of nafcillin in 10 mL of saline as an intravenous (IV) bolus
Trial: 2519941
Drug: 1 gram
RxNorm normalized name: guar gum 1 gram ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 gram of nafcillin in 50 mL of saline as a slow IV infusion over 15 minutes
Trial: 2519941
Drug: No nafcillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No nafcillin administration (Control group)
Trial: 31619654
Drug: Ultra-high hydrostatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-high hydrostatic pressurized brown rice (UHHPBR) intake group (n=20) consuming 100 g of UHHPBR and 100 g of white rice (WR) per day for 12 months
Trial: 31619654
Drug: White rice
RxNorm normalized name: White Rice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White rice (WR) intake group (n=20) consuming 200 g of WR per day for 12 months
Trial: 28301687
Drug: Ozone therapy
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone therapy (OG; n=20) applied at the point of greatest pain, three times per week for a total of six sessions.
Trial: 28301687
Drug: Sham ozone
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham ozone therapy (PG; n=20) applied at the point of greatest pain, three times per week for a total of six sessions.
Trial: 28301687
Drug: Ozone therapy
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone therapy (OG) at 3 months (T2) for temporal muscle PPT.
Trial: 28301687
Drug: Ozone therapy
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone therapy (OG) at 3 months (T2) for masseter muscle PPT.
Trial: 28301687
Drug: Ozone therapy
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone therapy (OG) at 3 months (T2) for lateral pole PPT.
Trial: 28301687
Drug: Ozone therapy
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone therapy (OG) for right lateral excursion at 3 months (T2).